Bicara Therapeutics Inc. financial data

Symbol
BCAX on Nasdaq
Location
245 Main Street, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.4M shares
Common Stock, Shares, Outstanding 54.4M shares
Common Stock, Value, Issued 7K USD
Weighted Average Number of Shares Outstanding, Basic 10.9M shares +1724%
Weighted Average Number of Shares Outstanding, Diluted 10.9M shares +1724%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 15.9M USD +130%
General and Administrative Expense 4.76M USD +83.9%
Operating Income (Loss) -20.6M USD -116%
Nonoperating Income (Expense) 3.15M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -17.5M USD +23.5%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -17.5M USD +23.5%
Earnings Per Share, Basic -1.6 USD/shares +95.8%
Earnings Per Share, Diluted -1.6 USD/shares +95.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 521M USD
Assets, Current 522M USD
Property, Plant and Equipment, Net 130K USD
Operating Lease, Right-of-Use Asset 414K USD
Other Assets, Noncurrent 2.12M USD
Assets 524M USD
Employee-related Liabilities, Current 1.81M USD
Liabilities, Current 14.5M USD
Operating Lease, Liability, Noncurrent 137K USD
Other Liabilities, Noncurrent 0 USD
Liabilities 14.6M USD
Retained Earnings (Accumulated Deficit) -200M USD
Stockholders' Equity Attributable to Parent 510M USD
Liabilities and Equity 524M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 500M shares
Common Stock, Shares, Issued 54.4M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 521M USD +1078%
Operating Lease, Liability, Current 308K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Additional Paid in Capital 710M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 2.03M USD +291%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares